IDEAYA Biosciences, Inc. announced the development candidate nomination of IDE251 on December 16, 2024. IDE251 is a potential first-in-class KAT6/7 dual inhibitor, marking the company's eighth development candidate in its precision medicine oncology pipeline.
IDE251 is designed to selectively inhibit both lysine acetyltransferase (KAT) 6 and 7, epigenetic modulators that support cancer cell survival. Preclinical data suggests an opportunity for enriched response in 8p11 amplified cancers, which occur in approximately 15% of breast cancer patients and up to 17.5% in squamous NSCLC.
IND-enabling studies are currently underway to support the potential clinical evaluation of IDE251 monotherapy in patients with breast and lung cancers with 8p11 amplification. IDEAYA is targeting an Investigational New Drug (IND) submission to the U.S. FDA in 2025 for IDE251.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.